{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:13:10Z","timestamp":1785510790709,"version":"3.56.0"},"reference-count":179,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"the Instituto de Salud Carlos III (ISCIII) (Spanish Ministry of Health)","doi-asserted-by":"publisher","award":["PI18\/00202"],"award-info":[{"award-number":["PI18\/00202"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"the Instituto de Salud Carlos III (ISCIII) (Spanish Ministry of Health)","doi-asserted-by":"publisher","award":["PI21\/00077"],"award-info":[{"award-number":["PI21\/00077"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"the Instituto de Salud Carlos III (ISCIII) (Spanish Ministry of Health)","doi-asserted-by":"publisher","award":["2021111073"],"award-info":[{"award-number":["2021111073"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"the Instituto de Salud Carlos III (ISCIII) (Spanish Ministry of Health)","doi-asserted-by":"publisher","award":["AI-2021-05"],"award-info":[{"award-number":["AI-2021-05"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003086","name":"Health Department, Basque Government","doi-asserted-by":"publisher","award":["PI18\/00202"],"award-info":[{"award-number":["PI18\/00202"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003086","name":"Health Department, Basque Government","doi-asserted-by":"publisher","award":["PI21\/00077"],"award-info":[{"award-number":["PI21\/00077"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003086","name":"Health Department, Basque Government","doi-asserted-by":"publisher","award":["2021111073"],"award-info":[{"award-number":["2021111073"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003086","name":"Health Department, Basque Government","doi-asserted-by":"publisher","award":["AI-2021-05"],"award-info":[{"award-number":["AI-2021-05"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"the Spanish Federation of Rare Diseases (FEDER)","doi-asserted-by":"publisher","award":["PI18\/00202"],"award-info":[{"award-number":["PI18\/00202"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"the Spanish Federation of Rare Diseases (FEDER)","doi-asserted-by":"publisher","award":["PI21\/00077"],"award-info":[{"award-number":["PI21\/00077"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"the Spanish Federation of Rare Diseases (FEDER)","doi-asserted-by":"publisher","award":["2021111073"],"award-info":[{"award-number":["2021111073"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"the Spanish Federation of Rare Diseases (FEDER)","doi-asserted-by":"publisher","award":["AI-2021-05"],"award-info":[{"award-number":["AI-2021-05"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AHUCE Foundation","award":["PI18\/00202"],"award-info":[{"award-number":["PI18\/00202"]}]},{"name":"AHUCE Foundation","award":["PI21\/00077"],"award-info":[{"award-number":["PI21\/00077"]}]},{"name":"AHUCE Foundation","award":["2021111073"],"award-info":[{"award-number":["2021111073"]}]},{"name":"AHUCE Foundation","award":["AI-2021-05"],"award-info":[{"award-number":["AI-2021-05"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Osteogenesis imperfecta is a rare genetic disorder characterized by bone fragility, due to alterations in the type I collagen molecule. It is a very heterogeneous disease, both genetically and phenotypically, with a high variability of clinical phenotypes, ranging from mild to severe forms, the most extreme cases being perinatal lethal. There is no curative treatment for OI, and so great efforts are being made in order to develop effective therapies. In these attempts, the in vivo preclinical studies are of paramount importance; therefore, serious analysis is required to choose the right murine OI model able to emulate as closely as possible the disease of the target OI population. In this review, we summarize the features of OI murine models that have been used for preclinical studies until today, together with recently developed new murine models. The bone parameters that are usually evaluated in order to determine the relevance of new developing therapies are exposed, and finally, current and innovative therapeutic strategies attempts considered in murine OI models, along with their mechanism of action, are reviewed. This review aims to summarize the in vivo studies developed in murine models available in the field of OI to date, in order to help the scientific community choose the most accurate OI murine model when developing new therapeutic strategies capable of improving the quality of life.<\/jats:p>","DOI":"10.3390\/ijms24010184","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T02:09:03Z","timestamp":1671761343000},"page":"184","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Murine Animal Models in Osteogenesis Imperfecta: The Quest for Improving the Quality of Life"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6087-5288","authenticated-orcid":false,"given":"Natividad","family":"Alcorta-Sevillano","sequence":"first","affiliation":[{"name":"Stem Cells and Cell Therapy Laboratory, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Plaza de Cruces S\/N, 48903 Barakaldo, Spain"},{"name":"Department of Cell Biology and Histology, University of Basque Country UPV\/EHU, 48940 Leioa, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1625-2865","authenticated-orcid":false,"given":"Arantza","family":"Infante","sequence":"additional","affiliation":[{"name":"Stem Cells and Cell Therapy Laboratory, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Plaza de Cruces S\/N, 48903 Barakaldo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iratxe","family":"Mac\u00edas","sequence":"additional","affiliation":[{"name":"Stem Cells and Cell Therapy Laboratory, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Plaza de Cruces S\/N, 48903 Barakaldo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6749-6288","authenticated-orcid":false,"given":"Clara I.","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Stem Cells and Cell Therapy Laboratory, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Plaza de Cruces S\/N, 48903 Barakaldo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/endrev\/bnab017","article-title":"Osteogenesis Imperfecta: Mechanisms and Signaling Pathways Connecting Classical and Rare OI Types","volume":"43","author":"Jovanovic","year":"2022","journal-title":"Endocr. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"dmm049398","DOI":"10.1242\/dmm.049398","article-title":"Dissecting the phenotypic variability of osteogenesis imperfecta","volume":"15","author":"Garibaldi","year":"2022","journal-title":"Dis. Model. Mech."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1530\/EJE-20-0299","article-title":"Osteogenesis imperfecta: An update on clinical features and therapies","volume":"183","author":"Marom","year":"2020","journal-title":"Eur. J. Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Botor, M., Fus-Kujawa, A., Uroczynska, M., Stepien, K.L., Galicka, A., Gawron, K., and Sieron, A.L. (2021). Osteogenesis Imperfecta: Current and Prospective Therapies. Biomolecules, 11.","DOI":"10.3390\/biom11101493"},{"key":"ref_6","first-page":"CD005088","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"10","author":"Dwan","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/jcpt.13056","article-title":"Potential risks of rare serious adverse effects related to long-term use of bisphosphonates: An overview of systematic reviews","volume":"45","author":"Lu","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1469-8749.2008.03222.x","article-title":"Effects of bisphosphonates in children with osteogenesis imperfecta: An AACPDM systematic review","volume":"51","author":"Castillo","year":"2009","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_9","first-page":"24","article-title":"Safety and efficacy of denosumab in children with osteogenesis imperfect\u2014A first prospective trial","volume":"16","author":"Franklin","year":"2016","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_11","first-page":"76","article-title":"Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI","volume":"18","author":"Trejo","year":"2018","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101148","DOI":"10.1016\/j.bonr.2021.101148","article-title":"Hypercalcemia following discontinuation of denosumab therapy: A systematic review","volume":"15","author":"Horiuchi","year":"2021","journal-title":"Bone Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11914-018-0434-z","article-title":"Anabolic Therapy for the Treatment of Osteoporosis in Childhood","volume":"16","author":"Ward","year":"2018","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.11138\/ccmbm\/2017.14.1.153","article-title":"Efficacy of teriparatide","volume":"14","author":"Leali","year":"2017","journal-title":"Clin. Cases Miner. Bone Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol. Pathol."},{"key":"ref_16","first-page":"41","article-title":"Animal models of osteogenesis imperfecta: Applications in clinical research","volume":"8","author":"Enderli","year":"2016","journal-title":"Orthop. Res. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1073\/pnas.90.5.1701","article-title":"Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: A model of human osteogenesis imperfecta","volume":"90","author":"Chipman","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"dmm049428","DOI":"10.1242\/dmm.049428","article-title":"Collagen (I) homotrimer potentiates the osteogenesis imperfecta (oim) mutant allele and reduces survival in male mice","volume":"15","author":"Lee","year":"2022","journal-title":"Dis. Model. Mech."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"12941","DOI":"10.1016\/S0021-9258(18)90635-6","article-title":"Osteogenesis imperfecta: Cloning of a pro-alpha 2(I) collagen gene with a frameshift mutation","volume":"259","author":"Pihlajaniemi","year":"1984","journal-title":"J. Biol. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1074\/jbc.M801982200","article-title":"Defective C-propeptides of the proalpha2(I) chain of type I procollagen impede molecular assembly and result in osteogenesis imperfecta","volume":"283","author":"Pace","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/jmg.21.4.257","article-title":"The clinical features of homozygous alpha 2(I) collagen deficient osteogenesis imperfecta","volume":"21","author":"Nicholls","year":"1984","journal-title":"J. Med. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Moffatt, P., Boraschi-Diaz, I., Marulanda, J., Bardai, G., and Rauch, F. (2021). Calvaria Bone Transcriptome in Mouse Models of Osteogenesis Imperfecta. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105290"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e10171","DOI":"10.1002\/jbm4.10171","article-title":"The Osteocyte Transcriptome Is Extensively Dysregulated in Mouse Models of Osteogenesis Imperfecta","volume":"3","author":"Zimmerman","year":"2019","journal-title":"JBMR Plus"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/jbmr.2414","article-title":"An investigation of the mineral in ductile and brittle cortical mouse bone","volume":"30","author":"Mukadam","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"104377","DOI":"10.1016\/j.jmbbm.2021.104377","article-title":"Intrafibrillar mineralization deficiency and osteogenesis imperfecta mouse bone fragility","volume":"117","author":"Samuel","year":"2021","journal-title":"J. Mech. Behav. Biomed. Mater."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1359\/jbmr.090720","article-title":"Variable bone fragility associated with an Amish COL1A2 variant and a knock-in mouse model","volume":"25","author":"Daley","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Kohler, R., Tastad, C.A., Creecy, A., and Wallace, J.M. (2021). Morphological and mechanical characterization of bone phenotypes in the Amish G610C murine model of osteogenesis imperfecta. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0255315"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/jbmr.2824","article-title":"Osteoblast Malfunction Caused by Cell Stress Response to Procollagen Misfolding in \u03b12(I)-G610C Mouse Model of Osteogenesis Imperfecta","volume":"31","author":"Mirigian","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e2201273","DOI":"10.1002\/advs.202201273","article-title":"ER, Mitochondria, and ISR Regulation by mt-HSP70 and ATF5 upon Procollagen Misfolding in Osteoblasts","volume":"9","author":"Gorrell","year":"2022","journal-title":"Adv. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00223-018-0461-x","article-title":"Early Fracture Healing is Delayed in the Col1a2","volume":"103","author":"Besio","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"37923","DOI":"10.1074\/jbc.274.53.37923","article-title":"Use of the Cre\/lox recombination system to develop a non-lethal knock-in murine model for osteogenesis imperfecta with an alpha1(I) G349C substitution. Variability in phenotype in BrtlIV mice","volume":"274","author":"Forlino","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/pmic.200600919","article-title":"Differential expression of both extracellular and intracellular proteins is involved in the lethal or nonlethal phenotypic variation of BrtlIV, a murine model for osteogenesis imperfecta","volume":"7","author":"Forlino","year":"2007","journal-title":"Proteomics"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1016\/j.jprot.2012.01.038","article-title":"Differential response to intracellular stress in the skin from osteogenesis imperfecta Brtl mice with lethal and non lethal phenotype: A proteomic approach","volume":"75","author":"Bianchi","year":"2012","journal-title":"J. Proteom."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1359\/jbmr.080804","article-title":"Cellular mechanism of decreased bone in Brtl mouse model of OI: Imbalance of decreased osteoblast function and increased osteoclasts and their precursors","volume":"23","author":"Uveges","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jsb.2010.08.003","article-title":"Nanoscale morphology of Type I collagen is altered in the Brtl mouse model of Osteogenesis Imperfecta","volume":"173","author":"Wallace","year":"2011","journal-title":"J. Struct. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jmbbm.2018.10.010","article-title":"Cortical bone properties in the Brtl\/+ mouse model of Osteogenesis imperfecta as evidenced by acoustic transmission microscopy","volume":"90","author":"Blouin","year":"2019","journal-title":"J. Mech. Behav. Biomed. Mater."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1359\/JBMR.040111","article-title":"Brittle IV mouse model for osteogenesis imperfecta IV demonstrates postpubertal adaptations to improve whole bone strength","volume":"19","author":"Kozloff","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.matbio.2007.06.005","article-title":"Selective retention and degradation of molecules with a single mutant alpha1(I) chain in the Brtl IV mouse model of OI","volume":"26","author":"Forlino","year":"2007","journal-title":"Matrix Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/jbmr.2177","article-title":"First mouse model for combined osteogenesis imperfecta and Ehlers-Danlos syndrome","volume":"29","author":"Chen","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/0022034516637045","article-title":"Craniofacial and Dental Defects in the Col1a1Jrt\/+ Mouse Model of Osteogenesis Imperfecta","volume":"95","author":"Eimar","year":"2016","journal-title":"J. Dent. Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Lisse, T.S., Thiele, F., Fuchs, H., Hans, W., Przemeck, G.K., Abe, K., Rathkolb, B., Quintanilla-Martinez, L., Hoelzlwimmer, G., and Helfrich, M. (2008). ER stress-mediated apoptosis in a new mouse model of osteogenesis imperfecta. PLoS Genet., 4.","DOI":"10.1371\/journal.pgen.0040007"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1093\/hmg\/dds183","article-title":"Cardiopulmonary dysfunction in the Osteogenesis imperfecta mouse model Aga2 and human patients are caused by bone-independent mechanisms","volume":"21","author":"Thiele","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.bone.2019.07.021","article-title":"A novel transgenic murine model with persistently brittle bones simulating osteogenesis imperfecta type I","volume":"127","author":"Liu","year":"2019","journal-title":"Bone"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ydbio.2018.05.017","article-title":"The versatile hippo pathway in oral-maxillofacial development and bone remodeling","volume":"440","author":"Xiang","year":"2018","journal-title":"Dev. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.4161\/cc.6.14.4474","article-title":"Components of the collagen prolyl 3-hydroxylation complex are crucial for normal bone development","volume":"6","author":"Marini","year":"2007","journal-title":"Cell Cycle"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2006.08.039","article-title":"CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta","volume":"127","author":"Morello","year":"2006","journal-title":"Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.bone.2009.10.037","article-title":"CRTAP deficiency leads to abnormally high bone matrix mineralization in a murine model and in children with osteogenesis imperfecta type VII","volume":"46","author":"Morello","year":"2010","journal-title":"Bone"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/jbmr.2363","article-title":"A transgenic mouse model of OI type V supports a neomorphic mechanism of the IFITM5 mutation","volume":"30","author":"Lietman","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bone.2017.11.013","article-title":"Crispr-Cas9 engineered osteogenesis imperfecta type V leads to severe skeletal deformities and perinatal lethality in mice","volume":"107","author":"Rauch","year":"2018","journal-title":"Bone"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"11717","DOI":"10.1038\/s41598-017-10343-9","article-title":"An ENU-induced splice site mutation of mouse Col1a1 causing recessive osteogenesis imperfecta and revealing a novel splicing rescue","volume":"7","author":"Tabeta","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.bbrc.2019.03.091","article-title":"Deficiency of lysyl hydroxylase 2 in mice causes systemic endoplasmic reticulum stress leading to early embryonic lethality","volume":"512","author":"Kasamatsu","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"116242","DOI":"10.1016\/j.bone.2021.116242","article-title":"Decrease of lysyl hydroxylase 2 activity causes abnormal collagen molecular phenotypes, defective mineralization and compromised mechanical properties of bone","volume":"154","author":"Saito","year":"2022","journal-title":"Bone"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/humu.22139","article-title":"Absence of FKBP10 in recessive type XI osteogenesis imperfecta leads to diminished collagen cross-linking and reduced collagen deposition in extracellular matrix","volume":"33","author":"Barnes","year":"2012","journal-title":"Hum. Mutat."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1093\/hmg\/ddu117","article-title":"The swaying mouse as a model of osteogenesis imperfecta caused by WNT1 mutations","volume":"23","author":"Joeng","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1136\/jmedgenet-2013-101567","article-title":"Mutations in WNT1 are a cause of osteogenesis imperfecta","volume":"50","author":"Fahiminiya","year":"2013","journal-title":"J. Med. Genet."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41413-021-00170-0","article-title":"The WNT1G177C mutation specifically affects skeletal integrity in a mouse model of osteogenesis imperfecta type XV","volume":"9","author":"Vollersen","year":"2021","journal-title":"Bone Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"116451","DOI":"10.1016\/j.bone.2022.116451","article-title":"Alterations of bone material properties in growing Ifitm5\/BRIL p.S42 knock-in mice, a new model for atypical type VI osteogenesis imperfecta","volume":"162","author":"Hedjazi","year":"2022","journal-title":"Bone"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"109015","DOI":"10.1016\/j.celrep.2021.109015","article-title":"Cytoplasmic polyadenylation by TENT5A is required for proper bone formation","volume":"35","author":"Gewartowska","year":"2021","journal-title":"Cell Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3389\/fendo.2018.00666","article-title":"An Optimized Approach to Perform Bone Histomorphometry","volume":"9","author":"Malhan","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bone.2017.03.051","article-title":"Open source software for semi-automated histomorphometry of bone resorption and formation parameters","volume":"99","author":"Rose","year":"2017","journal-title":"Bone"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/dvdy.166","article-title":"Dental and craniofacial defects in the Crtap","volume":"249","author":"Xu","year":"2020","journal-title":"Dev. Dyn."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bone.2016.04.011","article-title":"Bone mineral properties in growing Col1a2(+\/G610C) mice, an animal model of osteogenesis imperfecta","volume":"87","author":"Masci","year":"2016","journal-title":"Bone"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41597-021-01012-8","article-title":"Murine femur micro-computed tomography and biomechanical datasets for an ovariectomy-induced osteoporosis model","volume":"8","author":"Stephens","year":"2021","journal-title":"Sci. Data"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e10473","DOI":"10.1002\/jbm4.10473","article-title":"The Effect of Single Versus Group \u03bcCT on the Detection of Trabecular and Cortical Disease Phenotypes in Mouse Bones","volume":"5","author":"Kohler","year":"2021","journal-title":"JBMR Plus"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/jbmr.141","article-title":"Guidelines for assessment of bone microstructure in rodents using micro-computed tomography","volume":"25","author":"Bouxsein","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/bonekey.2014.115","article-title":"Contributions of Raman spectroscopy to the understanding of bone strength","volume":"4","author":"Mandair","year":"2015","journal-title":"Bonekey Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00223-001-1006-1","article-title":"Shear strength and fatigue properties of human cortical bone determined from pure shear tests","volume":"69","author":"Turner","year":"2001","journal-title":"Calcif. Tissue Int."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Mac\u00edas, I., Alcorta-Sevillano, N., Rodr\u00edguez, C.I., and Infante, A. (2020). Osteoporosis and the Potential of Cell-Based Therapeutic Strategies. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051653"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1530\/JOE-17-0335","article-title":"Metabolic phenotype in the mouse model of osteogenesis imperfecta","volume":"234","author":"Tauer","year":"2017","journal-title":"J. Endocrinol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/1750-3841.14637","article-title":"Solanum muricatum Ameliorates the Symptoms of Osteogenesis Imperfecta In Vivo","volume":"84","author":"Wang","year":"2019","journal-title":"J. Food Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1196\/annals.1346.041","article-title":"Bisphosphonates: From bench to bedside","volume":"1068","author":"Russell","year":"2006","journal-title":"Ann. New York Acad. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1203\/00006450-200211000-00010","article-title":"Alendronate treatment for infants with osteogenesis imperfecta: Demonstration of efficacy in a mouse model","volume":"52","author":"McCarthy","year":"2002","journal-title":"Pediatr. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1016\/j.jbiomech.2008.09.028","article-title":"Bisphosphonate treatment in the oim mouse model alters bone modeling during growth","volume":"41","author":"Rao","year":"2008","journal-title":"J. Biomech."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bone.2004.10.006","article-title":"Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse","volume":"36","author":"Misof","year":"2005","journal-title":"Bone"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s002230010045","article-title":"A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta","volume":"69","author":"Camacho","year":"2001","journal-title":"Calcif. Tissue Int."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.bone.2019.06.018","article-title":"Zoledronate and Raloxifene combination therapy enhances material and mechanical properties of diseased mouse bone","volume":"127","author":"Powell","year":"2019","journal-title":"Bone"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1359\/jbmr.081238","article-title":"Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation","volume":"24","author":"Uveges","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bone.2013.06.003","article-title":"Fracture healing with alendronate treatment in the Brtl\/+ mouse model of osteogenesis imperfecta","volume":"56","author":"Meganck","year":"2013","journal-title":"Bone"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/jor.20469","article-title":"The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta","volume":"26","author":"Delos","year":"2008","journal-title":"J. Orthop. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/03008200903108472","article-title":"RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta","volume":"51","author":"Bargman","year":"2010","journal-title":"Connect. Tissue Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bonr.2018.06.008","article-title":"Loss of RANKL in osteocytes dramatically increases cancellous bone mass in the osteogenesis imperfecta mouse (oim)","volume":"9","author":"Zimmerman","year":"2018","journal-title":"Bone Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13023-014-0145-1","article-title":"Two years\u2019 experience with denosumab for children with osteogenesis imperfecta type VI","volume":"9","author":"Netzer","year":"2014","journal-title":"Orphanet. J. Rare. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.matbio.2015.12.008","article-title":"Raloxifene reduces skeletal fractures in an animal model of osteogenesis imperfecta","volume":"52","author":"Berman","year":"2016","journal-title":"Matrix Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"100246","DOI":"10.1016\/j.bonr.2020.100246","article-title":"6\u2019-Methoxy Raloxifene-analog enhances mouse bone properties with reduced estrogen receptor binding","volume":"12","author":"Powell","year":"2020","journal-title":"Bone Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrm3254","article-title":"Building strong bones: Molecular regulation of the osteoblast lineage","volume":"13","author":"Long","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.biocel.2016.05.015","article-title":"The role of the wnt\/\u03b2-catenin signaling pathway in formation and maintenance of bone and teeth","volume":"77","author":"Duan","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"279","DOI":"10.14310\/horm.2002.1111024","article-title":"The role of the Wnt signaling pathway in osteoblast commitment and differentiation","volume":"6","author":"Yavropoulou","year":"2007","journal-title":"Hormones"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"26770","DOI":"10.1074\/jbc.M504308200","article-title":"SOST is a ligand for LRP5\/LRP6 and a Wnt signaling inhibitor","volume":"280","author":"Tamai","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","article-title":"Role and mechanism of action of sclerostin in bone","volume":"96","author":"Sato","year":"2017","journal-title":"Bone"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1359\/jbmr.090411","article-title":"Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt\/beta-catenin signaling","volume":"24","author":"Lin","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1359\/jbmr.090730","article-title":"Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice","volume":"25","author":"Kramer","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.10.012","article-title":"Rapidly growing Brtl\/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment","volume":"71","author":"Sinder","year":"2015","journal-title":"Bone"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","article-title":"Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of osteogenesis imperfecta","volume":"28","author":"Sinder","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00198-014-2737-y","article-title":"Adult Brtl\/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength","volume":"25","author":"Sinder","year":"2014","journal-title":"Osteoporos. Int."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2016.01.001","article-title":"Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age","volume":"84","author":"Sinder","year":"2016","journal-title":"Bone"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/jbmr.3858","article-title":"Sclerostin Antibody-Induced Changes in Bone Mass Are Site Specific in Developing Crania","volume":"34","author":"Scheiber","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/jbmr.2198","article-title":"Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta","volume":"29","author":"Jacobsen","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bone.2017.04.016","article-title":"Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta","volume":"101","author":"Little","year":"2017","journal-title":"Bone"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bone.2014.06.015","article-title":"Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta","volume":"66","author":"Roschger","year":"2014","journal-title":"Bone"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/jbmr.2776","article-title":"Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-\/-) Mice, a Model of Recessive Osteogenesis Imperfecta","volume":"31","author":"Grafe","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bone.2019.04.011","article-title":"Sclerostin antibody reduces long bone fractures in the oim\/oim model of osteogenesis imperfecta","volume":"124","author":"Cardinal","year":"2019","journal-title":"Bone"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00223-019-00655-5","article-title":"Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim\/oim Mice","volume":"106","author":"Cardinal","year":"2020","journal-title":"Calcif. Tissue Int."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"705505","DOI":"10.3389\/fgene.2021.705505","article-title":"Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse","volume":"12","author":"Cardinal","year":"2021","journal-title":"Front. Genet."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/jbmr.3143","article-title":"BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial","volume":"32","author":"Glorieux","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bone.2017.07.005","article-title":"Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study","volume":"103","author":"Ishibashi","year":"2017","journal-title":"Bone"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nm.3544","article-title":"Excessive transforming growth factor-\u03b2 signaling is a common mechanism in osteogenesis imperfecta","volume":"20","author":"Grafe","year":"2014","journal-title":"Nat. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/jbmr.3617","article-title":"Effect of Anti-TGF-\u03b2 Treatment in a Mouse Model of Severe Osteogenesis Imperfecta","volume":"34","author":"Tauer","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e152571","DOI":"10.1172\/JCI152571","article-title":"Targeting TGF-\u03b2 for treatment of osteogenesis imperfecta","volume":"132","author":"Song","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e10530","DOI":"10.1002\/jbm4.10530","article-title":"Inhibition of TGF-\u03b2 Increases Bone Volume and Strength in a Mouse Model of Osteogenesis Imperfecta","volume":"5","author":"Greene","year":"2021","journal-title":"JBMR Plus"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1002\/ctm2.265","article-title":"Reiterative infusions of MSCs improve pediatric osteogenesis imperfecta eliciting a pro-osteogenic paracrine response: TERCELOI clinical trial","volume":"11","author":"Infante","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"830928","DOI":"10.3389\/fcell.2022.830928","article-title":"Circulating TGF-\u03b2 Pathway in Osteogenesis Imperfecta Pediatric Patients Subjected to MSCs-Based Cell Therapy","volume":"10","author":"Infante","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/jbmr.4540","article-title":"Antagonism Between PEDF and TGF-\u03b2 Contributes to Type VI Osteogenesis Imperfecta Bone and Vascular Pathogenesis","volume":"37","author":"Kang","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00223-001-1109-8","article-title":"Bone mineral content and density in the humerus of adult myostatin-deficient mice","volume":"71","author":"Hamrick","year":"2002","journal-title":"Calcif. Tissue Int."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.exger.2012.11.004","article-title":"Effects of the activin A-myostatin-follistatin system on aging bone and muscle progenitor cells","volume":"48","author":"Bowser","year":"2013","journal-title":"Exp. Gerontol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"30907","DOI":"10.1073\/pnas.2019263117","article-title":"Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A","volume":"117","author":"Lee","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"115036","DOI":"10.1016\/j.bone.2019.115036","article-title":"Novel ActRIIB ligand trap increases muscle mass and improves bone geometry in a mouse model of severe osteogenesis imperfecta","volume":"128","author":"Tauer","year":"2019","journal-title":"Bone"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/jbmr.3473","article-title":"Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta","volume":"33","author":"Jeong","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/jbmr.4223","article-title":"Impact of Genetic and Pharmacologic Inhibition of Myostatin in a Murine Model of Osteogenesis Imperfecta","volume":"36","author":"Omosule","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/jbmr.4529","article-title":"Combinatorial Inhibition of Myostatin and Activin A Improves Femoral Bone Properties in the G610C Mouse Model of Osteogenesis Imperfecta","volume":"37","author":"Omosule","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/(SICI)1096-9896(199802)184:2<212::AID-PATH996>3.0.CO;2-Z","article-title":"The retention of abnormal type I procollagen and correlated expression of HSP 47 in fibroblasts from a patient with lethal osteogenesis imperfecta","volume":"184","author":"Kojima","year":"1998","journal-title":"J. Pathol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbrc.2018.12.111","article-title":"Endoplasmic reticulum stress is induced in growth plate hypertrophic chondrocytes in G610C mouse model of osteogenesis imperfecta","volume":"509","author":"Scheiber","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/stem.1107","article-title":"Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: A new target for osteogenesis imperfecta pharmacological therapy","volume":"30","author":"Gioia","year":"2012","journal-title":"Stem Cells"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"119628","DOI":"10.1016\/j.lfs.2021.119628","article-title":"Amelioration of osteogenesis in iPSC-derived mesenchymal stem cells from osteogenesis imperfecta patients by endoplasmic reticulum stress inhibitor","volume":"278","author":"Duangchan","year":"2021","journal-title":"Life Sci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"dmm038521","DOI":"10.1242\/dmm.038521","article-title":"Cellular stress due to impairment of collagen prolyl hydroxylation complex is rescued by the chaperone 4-phenylbutyrate","volume":"12","author":"Besio","year":"2019","journal-title":"Dis. Model. Mech."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.bbadis.2018.02.002","article-title":"4-PBA ameliorates cellular homeostasis in fibroblasts from osteogenesis imperfecta patients by enhancing autophagy and stimulating protein secretion","volume":"1864","author":"Besio","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.matbio.2021.03.001","article-title":"Targeting cellular stress in vitro improves osteoblast homeostasis, matrix collagen content and mineralization in two murine models of osteogenesis imperfecta","volume":"98","author":"Garibaldi","year":"2021","journal-title":"Matrix Biol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e149636","DOI":"10.1172\/jci.insight.149636","article-title":"4PBA reduces growth deficiency in osteogenesis imperfecta by enhancing transition of hypertrophic chondrocytes to osteoblasts","volume":"7","author":"Scheiber","year":"2022","journal-title":"JCI Insight"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/jbmr.4501","article-title":"4-PBA Treatment Improves Bone Phenotypes in the Aga2 Mouse Model of Osteogenesis Imperfecta","volume":"37","author":"Duran","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jphs.2016.09.006","article-title":"Salubrinal improves mechanical properties of the femur in osteogenesis imperfecta mice","volume":"132","author":"Takigawa","year":"2016","journal-title":"J. Pharmacol. Sci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1111\/jcmm.14072","article-title":"Effect of rapamycin on bone mass and strength in the \u03b12(I)-G610C mouse model of osteogenesis imperfecta","volume":"23","author":"Bateman","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"21197","DOI":"10.1038\/s41598-020-78403-1","article-title":"Effect of immunosuppressants on a mouse model of osteogenesis imperfecta type V harboring a heterozygous Ifitm5 c.-14C\u2009>\u2009T mutation","volume":"10","author":"Hanagata","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1111\/jcmm.17437","article-title":"The effect of carbamazepine on bone structure and strength in control and osteogenesis imperfecta (Col1a2 +\/p.G610C ) mice","volume":"26","author":"Blank","year":"2022","journal-title":"J. Cell Mol. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.matbio.2016.03.005","article-title":"Makings of a brittle bone: Unexpected lessons from a low protein diet study of a mouse OI model","volume":"52","author":"Mertz","year":"2016","journal-title":"Matrix Biol."},{"key":"ref_134","first-page":"36","article-title":"The role of prostaglandins in the regulation of bone metabolism","volume":"313","author":"Kawaguchi","year":"1995","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1073\/pnas.062053399","article-title":"Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation","volume":"99","author":"Yoshida","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00264-007-0406-x","article-title":"Prostaglandin E(2) receptors in bone formation","volume":"31","author":"Li","year":"2007","journal-title":"Int. Orthop."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"115867","DOI":"10.1016\/j.bone.2021.115867","article-title":"Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta","volume":"145","author":"Chen","year":"2021","journal-title":"Bone"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1073\/pnas.92.11.4857","article-title":"Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice","volume":"92","author":"Pereira","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1073\/pnas.95.3.1142","article-title":"Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta","volume":"95","author":"Pereira","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/jbmr.5650101202","article-title":"Bone fragility in transgenic mice expressing a mutated gene for type I procollagen (COL1A1) parallels the age-dependent phenotype of human osteogenesis imperfecta","volume":"10","author":"Pereira","year":"1995","journal-title":"J. Bone Miner. Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.stemcr.2015.09.017","article-title":"Intrauterine Bone Marrow Transplantation in Osteogenesis Imperfecta Mice Yields Donor Osteoclasts and Osteomacs but Not Osteoblasts","volume":"5","author":"Millard","year":"2015","journal-title":"Stem Cell Rep."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00223-018-0504-3","article-title":"Bone Marrow Transplantation for Treatment of the Col1a2 +\/G610C Osteogenesis Imperfecta Mouse Model","volume":"104","author":"Lee","year":"2019","journal-title":"Calcif. Tissue Int."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/01.TP.0000159029.48678.93","article-title":"Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta","volume":"79","author":"Hassan","year":"2005","journal-title":"Transplantation"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"255","DOI":"10.5966\/sctm.2013-0090","article-title":"Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: A two-center experience","volume":"3","author":"Westgren","year":"2014","journal-title":"Stem Cells Transl. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1182\/blood.V97.5.1227","article-title":"Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta","volume":"97","author":"Horwitz","year":"2001","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"8932","DOI":"10.1073\/pnas.132252399","article-title":"Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone","volume":"99","author":"Horwitz","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1182\/blood-2011-12-400085","article-title":"Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms","volume":"120","author":"Otsuru","year":"2012","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1089\/scd.2013.0132","article-title":"Potential of human fetal chorionic stem cells for the treatment of osteogenesis imperfecta","volume":"23","author":"Jones","year":"2014","journal-title":"Stem Cells Dev."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"39656","DOI":"10.1038\/srep39656","article-title":"Counteracting bone fragility with human amniotic mesenchymal stem cells","volume":"6","author":"Ranzoni","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jcyt.2017.09.012","article-title":"Extracellular vesicles released from mesenchymal stromal cells stimulate bone growth in osteogenesis imperfecta","volume":"20","author":"Otsuru","year":"2018","journal-title":"Cytotherapy"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1634\/stemcells.2005-0430","article-title":"Progenitors systemically transplanted into neonatal mice localize to areas of active bone formation in vivo: Implications of cell therapy for skeletal diseases","volume":"24","author":"Wang","year":"2006","journal-title":"Stem Cells"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1634\/stemcells.2007-0466","article-title":"Distribution of single-cell expanded marrow derived progenitors in a developing mouse model of osteogenesis imperfecta following systemic transplantation","volume":"25","author":"Li","year":"2007","journal-title":"Stem Cells"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2007-08-105809","article-title":"Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice","volume":"111","author":"Guillot","year":"2008","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/blood-2010-05-287565","article-title":"Transplantation of human fetal blood stem cells in the osteogenesis imperfecta mouse leads to improvement in multiscale tissue properties","volume":"117","author":"Vanleene","year":"2011","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"70","DOI":"10.5966\/sctm.2011-0007","article-title":"Upregulating CXCR4 in human fetal mesenchymal stem cells enhances engraftment and bone mechanics in a mouse model of osteogenesis imperfecta","volume":"1","author":"Jones","year":"2012","journal-title":"Stem Cells Transl. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"180100","DOI":"10.1038\/sdata.2018.100","article-title":"Micro-computed tomography reconstructions of tibiae of stem cell transplanted osteogenesis imperfecta mice","volume":"5","author":"Ranzoni","year":"2018","journal-title":"Sci. Data"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1086\/383252","article-title":"High proportion of mutant osteoblasts is compatible with normal skeletal function in mosaic carriers of osteogenesis imperfecta","volume":"74","author":"Cabral","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1182\/blood-2004-02-0526","article-title":"A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow","volume":"104","author":"Wynn","year":"2004","journal-title":"Blood"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3389\/fimmu.2012.00297","article-title":"Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion","volume":"3","author":"Eggenhofer","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/stem.3133","article-title":"Engraftment of skeletal progenitor cells by bone-directed transplantation improves osteogenesis imperfecta murine bone phenotype","volume":"38","author":"Sinder","year":"2020","journal-title":"Stem Cells"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1182\/blood-2008-12-195859","article-title":"In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta","volume":"114","author":"Panaroni","year":"2009","journal-title":"Blood"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"110235","DOI":"10.1016\/j.biopha.2020.110235","article-title":"The synergistic effect of NELL1 and adipose-derived stem cells on promoting bone formation in osteogenesis imperfecta treatment","volume":"128","author":"Liu","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/jbmr.4326","article-title":"Modification of COL1A1 in Autologous Adipose Tissue-Derived Progenitor Cells Rescues the Bone Phenotype in a Mouse Model of Osteogenesis Imperfecta","volume":"36","author":"Liu","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1093\/gerona\/glt046","article-title":"The relevance of mouse models for investigating age-related bone loss in humans","volume":"68","author":"Jilka","year":"2013","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3389\/fendo.2019.00277","article-title":"Mouse Models and Online Resources for Functional Analysis of Osteoporosis Genome-Wide Association Studies","volume":"10","author":"Maynard","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/bonekey.2013.179","article-title":"A bone to pick with zebrafish","volume":"2","author":"Mackay","year":"2013","journal-title":"Bonekey Rep."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Valenti, M.T., Marchetto, G., Mottes, M., and Dalle Carbonare, L. (2020). Zebrafish: A Suitable Tool for the Study of Cell Signaling in Bone. Cells, 9.","DOI":"10.3390\/cells9081911"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cels.2020.02.007","article-title":"Phenomics-Based Quantification of CRISPR-Induced Mosaicism in Zebrafish","volume":"10","author":"Watson","year":"2020","journal-title":"Cell Syst."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/hmg\/ddx171","article-title":"The chaperone activity of 4PBA ameliorates the skeletal phenotype of Chihuahua, a zebrafish model for dominant osteogenesis imperfecta","volume":"26","author":"Gioia","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.matbio.2005.07.001","article-title":"Alpha 2(I) collagen deficient oim mice have altered biomechanical integrity, collagen content, and collagen crosslinking of their thoracic aorta","volume":"24","author":"Pfeiffer","year":"2005","journal-title":"Matrix Biol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1172\/JCI119519","article-title":"Collagen from the osteogenesis imperfecta mouse model (oim) shows reduced resistance against tensile stress","volume":"100","author":"Misof","year":"1997","journal-title":"J. Clin. Investig."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.matbio.2010.06.006","article-title":"Skeletal muscle weakness in osteogenesis imperfecta mice","volume":"29","author":"Gentry","year":"2010","journal-title":"Matrix Biol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1523-1755.2002.00451.x","article-title":"Novel collagen glomerulopathy in a homotrimeric type I collagen mouse (oim)","volume":"62","author":"Phillips","year":"2002","journal-title":"Kidney Int."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.bpj.2009.04.059","article-title":"Molecular and mesoscale mechanisms of osteogenesis imperfecta disease in collagen fibrils","volume":"97","author":"Gautieri","year":"2009","journal-title":"Biophys. J."},{"key":"ref_175","first-page":"1","article-title":"Muscle abnormalities in osteogenesis imperfecta","volume":"17","author":"Veilleux","year":"2017","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1007\/s11999-015-4268-z","article-title":"Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?","volume":"473","author":"Boskey","year":"2015","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s10439-013-0793-7","article-title":"Gender-dependence of bone structure and properties in adult osteogenesis imperfecta murine model","volume":"41","author":"Yao","year":"2013","journal-title":"Ann. Biomed. Eng."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"116378","DOI":"10.1016\/j.bone.2022.116378","article-title":"Combination treatment with growth hormone and zoledronic acid in a mouse model of Osteogenesis imperfecta","volume":"159","author":"Lee","year":"2022","journal-title":"Bone"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/GRF.0000000000000656","article-title":"Mesenchymal Stem Cell Therapy for Osteogenesis Imperfecta","volume":"64","author":"David","year":"2021","journal-title":"Clin. Obstet. Gynecol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/1\/184\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:47:42Z","timestamp":1760147262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/1\/184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":179,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ijms24010184"],"URL":"https:\/\/doi.org\/10.3390\/ijms24010184","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]}}}